Ahmedabad Current Affairs - 2020
On 2nd July 2020, the Drug Controller General of India (DCGI) has given approval for human clinical trials to Ahmedabad based Cadila Healthcare Limited (Zydus Healthcare). The permission is for the Phase-I and Phase-II clinical trials of the vaccine.
Zydus Healthcare’s COVID-19 vaccine become the 2nd Indigenously developed vaccine to get the permission of the DCGI for human clinical trials after Bharat Biotech’s COVAXIN. The human clinical trials for the vaccine are expected to be completed in three months as per media reports.
Success during Clinical Trials on Animals
The approval for the human clinical trials was given by the DCGI based on the recommendation made by the COVID-19 Subject Expert Committee. The Subject Expert Committee recommendation was on the basis of the data provided to the DCGI by Zydus Healthcare on the success of their COVID-19 vaccine during clinical trials on the animals.
With respect to safety and immunogenicity, the potential novel coronavirus vaccine developed by the Zydus Healthcare was found to be successful during animal studies, this was informed by the Drug Controller General of India Dr. V.G. Somani.
Headquartered in Gujarat’s Ahmedabad, Zydus Healthcare is one of the leading manufacturers of generic drugs in India. It was founded in the year 1952 by Ramanbhai Patel. The company is also known as Cadila Healthcare Limited or Zydus Cadila Healthcare Limited.
Tags: Ahmedabad • Bharat Biotech Limited • COVAXIN Vaccine • COVID-19 • Dr V.K. Somani
A Letter of Intent (LoI) was exchanged between Ahmedabad and Japanese city of Kobe for a sister city partnership. The LoI was exchanged in presence of Indian Prime Minister Narendra Modi, who visited Kobe to address a large Indian diaspora event.
Authorities from Japanese city of Kobe exchanged Letter of Intent (LoI) with their counterparts in Ahmedabad for Ahmedabad-Kobe Sister City Partnership.
This development will further pave the way for an enhanced economic relationship as well as a cultural exchange between two vibrant cities as well as between India and Japan.
In November 2016, PM Narendra Modi and his Japanese counterpart Shinzo Abe inked a sister-state relationship Memorandum of Understanding for Gujarat and Hyogo prefecture, a Japanese prefecture in Kansai region of Japan’s main island, Honshu. Kobe is capital city of Hyogo. During his visit, Modi had also visited a bullet train plant in Kobe.
MoU then signed was sought to promote mutual cooperation between Gujarat and Hyogo in fields of academics, cultural cooperation, business, environmental protection and disaster management.
What is a sister city?
The sister cities or twin towns concept is a legal and social agreement between towns, cities, oblasts, counties, provinces, prefectures, states, regions between two different countries to promote cultural as well as commercial ties.
This plan was conceived after World War II ended so as to promote peaceful coexistence and to encourage trade and tourism.
In diplomacy, the concept of sister cities is seen as a way for enhancing strategic ties between two nations, both cultural and economic.
India has signed sister city agreements with: China, Australia, United States, South Korea (RoK), Russia, Canada, Germany, Belarus, Mauritius, Hungary, Jordan, Bangladesh, Lithuania and Portugal.
In India there is no such part where Japan’s projects or investments have not left its mark in similar manner, talent and manpower of India are also contributing towards strengthening Japan. This partnership has risen from a time when both countries collaborated in building cars and are collaborating in building a bullet train.
India is also planning to run its 1st bullet train between Mumbai and Ahmedabad with the help of Japan. The first stretch of ambitious project is expected to be completed by 2022.